FDA D.I.S.C.O.: A new treatment for acute myelogenous leukemia

(5:1econd)

FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma

(5:31)

FDA D.I.S.C.O. Burst Edition: FDA approval of ABECMA (idecabtagene vicleucel) the first FDA appro...

(3:31)

FDA D.I.S.C.O. Burst Edition: FDA approval of Trodelvy (sacituzumab govitecan-hziy) for HR-positi...

(4:1econd)

FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval Transcript

(6:1econd)

FDA D.I.S.C.O. Burst Edition: FDA approval of Omisirge (omidubicel-onlv) to reduce time to neutro...

(3:31)

AMAZING INVENTIONS YOU SHOULD SEE

(1:3:19)

Understand the Applicability of FDA’s Computer Software Assurance Guidance to Data Integrity

(1:6:45)

What is FDA Approval?

(11:32)

What is FDA Project Optimus and How Will it Impact Oncology Drug Development?

(59:)

Navigating FDA's Drug Information Resources

(50:52)

Dollar - Oh L'Amour - TOTP 1988

(2:42)

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for unresectable advanced ...

(3:31)

FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-posit...

(5:1econd)

FDA D.I.S.C.O. Burst Edition: FDA approval of Retevmo (selpercatinib) for advanced or metastatic ...

(4:1econd)

The Spirit of The July Uprising | Memory, Amnesia \u0026 The Museum | Ebadur Rahman, PhD

(2:2:39)

FDA D.I.S.C.O.: A new drug approval for IDH1 positive relapsed or refractory Acute Myeloid Leukemia

(6:31)

FDA D.I.S.C.O.: FDA approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma

(6:31)

FDA D.I.S.C.O. Burst Edition: FDA approval of Imfinzi (durvalumab) for adult patients with locall...

(3:31)

FDA D.I.S.C.O.: First FDA approval of a CAR T-cell immunotherapy

(6:1econd)

FDA D.I.S.C.O. Burst Edition: FDA approval of Lynparza (olaparib), with abiraterone and prednison...

(3:31)

FDA D.I.S.C.O. Burst Edition: FDA approval of Xalkori (crizotinib) for ALK-positive inflammatory ...

(3:1econd)

FDA D.I.S.C.O.: A new drug approval for non-metastatic castration-resistant prostate cancer

(5:1econd)

FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur

(3:21)

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

(6:1econd)

FDA D.I.S.C.O.: First biosimilar approval for the treatment of cancer

(8:31)

FDA D.I.S.C.O.: FDA approval of Cablivi for acquired thrombotic thrombocytopenic purpura

(8:1econd)

FDA D.I.S.C.O. Burst Edition: FDA approval of Fruzaqla (fruquintinib) for adult patients with met...

(3:31)

FDA D.I.S.C.O.: FDA approval of larotrectinib for advanced malignancies with NTRK gene fusion

(7:31)

FDA D.I.S.C.O. Burst Edition: FDA approval of Brukinsa (zanubrutinib) for adult patients with Wal...

(3:1econd)